Presented by
Management Forum

Biotechnology for the Non-Biotechnologist

An ideal course for non-scientists and scientists who need to understand the basic theory, principles, techniques and potential of biotechnology.

1-3 Dec 2021 + 3 more dates

Enrol now

  • Format: Classroom, Live online
  • CPD: 18 hours for your records
  • Certificate of completion

Course overview

The importance of the biotech industry has increased significantly over recent years and biotech companies now dominate the new drug pipeline. The industry is gaining momentum and advancements in biomedical science and increased innovation hold vast potential for the growth of the biotech market.

This intensive three-day course will provide an overview of how biotech products are being developed and manufactured, and discuss the scientific and regulatory environment. The interactive programme will cover the latest advances in regulation, including biosimilars and advanced therapies, and address the role and importance of patents within biotech, including what actually can be patented.

Benefits of attending:

  • Gain an introduction to the fundamental principles of biotechnology
  • Improve your understanding of the key techniques used by biotechnologists
  • Understand the key regulatory considerations for biopharmaceuticals
  • Discuss advances in regulation – biosimilars and advanced therapies
  • Learn how to identify potential patents, and why and how they must be protected

Who should attend?

This course is ideal for non-scientists and scientists needing to understand the basic theory, principles, techniques and potential of biotechnology.

It will be relevant for anyone needing either an overview or refresher, particularly those working in:

  • Quality assurance
  • Regulatory affairs
  • Legal and IP
  • Business development
  • Sales and marketing
  • Engineering
  • Finance
  • Clinical
  • Training
  • Project management

Enrol now

The Biotechnology for the Non-Biotechnologist course will cover:

Introduction to biotechnology

  • Historical perspective
  • Diversity of biotechnology products
  • Impact on society
  • Product development overview

Introduction to molecular biology

  • DNA, RNA, genes, plasmids and vectors
  • Protein synthesis – transcription and translation

Re-expression of proteins

  • Recombinant DNA techniques
  • Monoclonal antibodies – from mouse to human
  • Transgenic animals and plants

Development of production organisms

  • Transfection
  • Selection
  • Preservation

Fermentation technology and large-scale production

  • Types of fermenters
  • Fermentation basics
  • Modes of operation
  • Process development

Analysis of biopharmaceuticals

  • Biological activity
  • Physicochemical characterisation
  • Purity, impurities and contaminants

Formulation design of biopharmaceuticals

  • Factors affecting degradation
  • Choice of excipients
  • Prolonging shelf life

Product recovery and purification

  • Cell harvesting and removal
  • Clarification – intracellular and extracellular proteins
  • Chromatographic techniques

Process optimisation and scale-up

  • Scale-up strategies
  • Strain improvement
  • Media improvement
  • Process improvement

Process economics

  • Drug development and bioprocess economics
  • Optimising bioprocess economics
  • Manufacturing make or buy
  • Future manufacturing alternatives

Patenting biotech inventions

  • What is a patent?
  • What are the basic criteria for patentability?
  • What can be patented?
  • Can you patent genes, proteins, hybridomas, and stem cells?

Patent workshop

  • How to recognise what is patentable
  • Drafting claims to biotech inventions
  • Maximising protection for an invention
  • Understanding the examination process
  • Enforcing patents

Regulatory considerations of biopharmaceuticals

  • General principles
  • Product quality and control
  • Pre-clinical safety

Application of regulatory principles

  • What do regulators want?
  • Specifications
  • Product characterisation
  • Assessment of process change
  • Comparability guidance and strategy

Advances in regulation: biosimilars

  • Comparability, equivalence and biosimilarity
  • Biosimilars guidance
  • Guidance vs practice – a case study

Advances in regulation: advanced therapies

  • Gene therapy
  • Cell therapy
  • Tissue-engineered products

Enrol now

Adekunle Onadipe

Dr Adekunle Onadipe is an Associate Research Fellow in Bioprocess R&D, Cell Line Development at Pfizer Inc. USA. He leads a group of scientists responsible for the construction, development and characterization of mammalian and microbial cell lines for biotherapeutics and vaccines production. His group is also involved in the scale-up of bioprocesses from bench top to pilot scale bioreactors and process development for the establishment of cell banks to support the manufacture of biopharmaceutical products for early phase clinical trials.

Kunle joined Pfizer Limited in the UK in 2005 in Discovery Biology with responsibility for optimizing cell culture processes for the production of cell-based assay reagents. Prior to this he worked for 15 years at Lonza Biologics plc., in Slough UK where, as a Principal Group Leader in cell culture process development, he was responsible for constructing and developing production mammalian cell lines and culture processes, subsequently transferring them to full-scale production for clinical trials.

A microbiologist by training, Kunle has been involved in the production of biopharmaceuticals for more than 30 years and has a broad experience of microbial and mammalian cell culture methods. He obtained his PhD in Microbiology from the University of Surrey, Guildford UK.

More details

Adrian Haines

Dr Adrian Haines is the Head of Science and Technology at Sobi AG, based in Geneva, Switzerland. Adrian has extensive experience in generating mammalian cell lines suitable for the GMP production of biologics and is extensively involved in the scientific oversight of both upstream and downstream process development, and process characteristion studies prior to regulatory filings. He joined the company (then Novimmune) in 2015 and prior to this he worked at Lonza Biologics in the UK working on projects to develop new technologies and processes for generating manufacturing cell lines. Before that he worked for ML Laboratories/Cobra Research developing UCOE technologies for the expression of proteins in mammalian cells and at Therexsys Ltd, developing antibody targeted gene therapies. Prior to this he worked at Celltech Research Ltd, generating radiolabelling and cross-linking technologies for antibodies. A biochemist by training, he has been involved in the protein chemistry and production of monoclonal antibodies ~30 years, starting with his PhD where he generated monoclonal antibodies (using hybridoma technology) for the diagnosis of prostate cancer. He received a bachelor degree from Imperial College, London, and a PhD from St Thomas’ Hospital Medical School, University of London.

More details

Peter O'Callaghan

Peter O’Callaghan holds BSc and PhD degrees in Genetics from Newcastle University. Since graduation he has gained over 10 years’experience in biotechnology research and development in academia and industry, during which time he co-authored patents as well as research articles and reviews in international peer-reviewed scientific journals and books.
Since 2011 he has been woking in the New Expression Technologies group at Lonza Biologics in Cambridge. He works as an Principle Scientist where he is responsible for the development and commercial implementation of new gene expression technologies, cell lines, and tools for recombinant therapeutic protein production using CHO cell lines. He also leads R&D strategies for developing next-generation technologies and processes, in addition to supporting commercial launch and associated promotional work

More details

Kate Smith

Kate Smith is currently Principal Scientist, Development Services, at BioReliance, UK, part of the Merck Group. In this position she is reponsible for providing technical supprt to both colleagues adn clients on the deign, execution and interpretation of viral clearance studies. Prior to transitioning into Development services Kate was responsible for managing the team involved in the preparatino of cell banks, viral seeds stocks and production of clinical lots of virus. .
Prior to joining BioReliance Kate was a Principal Group Leader in the Purification Development Group at Lonza Biologics, plc. She has more than 18 years experience in the development, scale-up, transfer and validation of purification processes for monoclonal antibodies and recombinant proteins from mammalian cell cultures. Her area of expertise is the design and management of Viral and DNA reduction studies used to support product safety.

More details

Alison Sykes

Alison Sykes is Director Physico-Chem Analytics, for Fresenius-Kabi, SwissBio Sim, a post she took up in 2017. She was formerly a Director within the Biosimilar Unit of Merch Serono and Biosimilar Technical Director within Analytical Services at Lonza Biologics plc responsible for oversight and definition of all analytical activities relating to pre-clinical and clinical development of Biosimilars derived from mammalian and microbial cell culture. She had worked for Lonza for 25 years, responsible for running various different analytical teams and functions including cell culture support, method development and validation, stability and formulation and protein characterisation. She has been responsible for set-up and establishing FDA and MHRA approved laboratories and providing technical and advisory support for CMC development of biopharmaceuticals from pre-clinical through to clinical phases, including several successful BLA licence applications. A biochemist by training, she started her career working for the National Health Service and then moved to NIBSC. Her experience here on the human side of the drug industry and the need for global standards in protein drug development helped drive her enthusiasm for detailed analysis and characterisation of safe and efficacious biopharmaceuticals.

More details

Philip Webber

Dr. Philip Webber obtained his first degree from Cambridge University, UK (Natural Sciences, Genetics) and then carried out research on the regulation of brain-specific genes at Warwick University, UK, where he obtained his PhD.
He qualified as a UK Chartered Patent Attorney and European Patent Attorney with Dehns (formerly Frank B. Dehn & Co.) London and Oxford, and is now a partner in their Life Sciences Group. He has a worldwide client-base including clients from the UK, Scandinavia, the US and Japan. Amongst other things, his work involves the preparation and filing of patent applications in Europe and throughout the world; acting for his clients in opposition procedures at the European Patent Office; and searching for and advising his clients on the relevance of competitors’ patents. He is an active member of the Life Sciences Committee of the UK Chartered Institute of Patent Attorneys (CIPA). He has spoken at a number of European conferences and on BBC Radio on the patenting of biotech inventions, as well as publishing a number of papers in this area.

More details

Rhydian Howells

Rhydian Howells, associate director of regulatory affairs at Diamond Pharma services a Propharma group company. 20 years’ experience in the industry, 10 years at a large contract manufacturer developing manufacturing processes and analytical offerings for biological products followed by 10 years in regulatory CMC roles supporting clients with clinical development and marketing authorisation activities for large molecules and advanced therapies.

More details

Book Biotechnology for the Non-Biotechnologist Classroom/Live online training

1-3 Dec 2021

Classroom
London venue TBC

00:00-00:00 UK (London)
Course code 11385

  • GBP 1,549 1,849
  • EUR 2,169 2,589
  • USD 2,416 2,884

Until 27 Oct

Limited places remaining

  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

In your basket 

7-9 Mar 2022

Live online

09:00-17:00 UK (London) (UTC+00)
10:00-18:00 Paris (UTC+01)
04:00-12:00 New York (UTC-05)
Course code 11614

  • GBP 1,249 1,549
  • EUR 1,809 2,229
  • USD 2,056 2,524

Until 31 Jan

In your basket 

27-29 Jun 2022

Classroom
London venue TBC

00:00-00:00 UK (London)
Course code 11876

  • GBP 1,549 1,849
  • EUR 2,169 2,589
  • USD 2,416 2,884

Until 23 May

  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

In your basket 

28-30 Sep 2022

Live online

09:00-17:00 UK (London) (UTC+01)
10:00-18:00 Paris (UTC+02)
04:00-12:00 New York (UTC-04)
Course code 11707

  • GBP 1,249 1,549
  • EUR 1,809 2,229
  • USD 2,056 2,524

Until 24 Aug

In your basket 

Reviews of IPI's Biotechnology for the Non-Biotechnologist training course


The content was excellent and all presenters were clearly SMEs, who managed to explain much of the complex content in an understandable way.

Sep 29 2021

Sunil Singh
Director, Regulink Ltd

Apr 14 2021

Excellent. Really enjoyed and learned a lot.

Anthony Barker
Director - Regulatory CMC, Home Address

Apr 14 2021

The presentations were well prepared in general and I learned a lot.

Katja Pecjak
Director of Regulatory Affairs & QPPV, Billev farmacija vzhod d.o.o

Sep 30 2020

I felt like the three days flowed together really well, first giving a basic understanding of the biology side of these products, how they are made and then their uses.

Laura Jones
Regulatory CMC Manager, AstraZeneca

Sep 30 2020

Really interesting, and a great introduction to someone with little/no knowledge of biotechnology. Also great that it went from scientific processes through to industrial processes. Nicely laid out. Well worth the three days!

Jackie Knipe
IP Paralegal, ALBUMEDIX LTD

Apr 10 2019

Well-balanced set of topics – nothing of importance seems to have been left out. The perfect level of detail for me as a biotech program leader/manager with a non-biotech scientific background.

Sergio Freitas
Development Program Lead, Tillotts Pharma AG

Sep 25 2019

A good general introduction that managed to make this very technical subject matter understandable to those with little scientific background, or as a refresher to those who may have graduated many years previously.

Matthew Jordan
Imerys Minerals

Sep 25 2019

The course was comprehensive and the speakers were both subject matter experts and very good presenters. I really enjoyed the three days.

Linnea Elrington
VP, Head of HR, Silence Therapeutics

Sep 25 2019

I thought it was a really interesting overview of biotechnology, from the specific scientific processes all the way through to the industry trends. I appreciated the discussion of advantages/ disadvantages and challenges of various methods and the industry as a whole, as I think this added a lot of context. This was beneficial for me when I was trying to apply what I had learned in the day to my specific company's context.

Sian Gilfillan
Marketing and Communications Associate, Albumedix

Apr 10 2019

I wanted to learn the basics of biologicals research and establishment/characterization of MCB. I also wanted to learn more on biologics manufacture and registration/filing. All of this was accomplished.

Michael Vestling
Regulatory and Quality Manager, INTERVACC AB

Apr 10 2019

I really appreciated the course and learned a lot.

Natacha Gonzalez
CMC Dossier & Compliance Specialist, Merck

Apr 10 2019

The content and presentation were very good.

Rutger Vandiest
Sr Director - Head of Sales, Bavarian Nordic

Sep 26 2018

Excellent course – I learned a lot despite having worked as an in-house lawyer for a CMO for almost 5 years. The speakers were highly competent, engaged, knowledgable and able to answer all of my questions (and I had quite a few). Overall, a course I can highly recommend to other in-house lawyers.

Anna Damgaard Jensen
Head of Legal , AOP Orphan Pharma

Sep 26 2018

The course is prepared to explain biotechnology in a very clear and complete way. It is intensive and you have to be focused to follow, but it's definitely worth the effort!

Roza Puzio
European Projects Manager, Atlanpole

Apr 25 2018

All speakers were excellent and explained complex ideas very well. Fantastic, applicable course, presented really well. Great refresher course on molecular biology.

Luisa Teixeira
Account Manager, Owen Mumford Ltd

Apr 25 2018

Very good with lots of content. Thank you!

Falk Neukirch
CFO, Vita 34 AG

Apr 25 2018

Highly qualified speakers.

Merecedes Rodríguez Rojas
Business Manager, CZ Veterinaria, S.A

Apr 25 2018

A good mix of speakers – the course was useful for me.

Oliver Dale
Senior Specialist, MSD

Apr 25 2018

Interesting course with good quality speakers.

Anna Sarao
Regulatory Affairs Project Manager, Servier

Apr 26 2017

Very positive opinion. Content very clear. Interaction with speakers was fruitful. Good to have each day a summary of what was learnt the day before.

Vanessa Brousset
Manager Europe, Galderma R&D

Apr 26 2017

Very good. Broad overview. Friendly audience

Jean-Paul Chappuis
Galderma International

Apr 26 2017

Speakers - well experienced. Content - well structured presentations

Lina Cacic
Regulatory Affairs Advisor, Agency for Medicinal Products and Medical Devices of Croatia (HALMED)

Sep 27 2017

Very good.

Rabiea Abdullah
Senior Regulatory Specialist, MSD

Sep 27 2017

Well-structured training, clear presentations and explanations.

Oliver Jungmann
Global Head Drug Substance Technical Lead, F. Hoffmann-La Roche Ltd.

Sep 27 2017

Very good course, a bit condensed, very good speakers

Erik Andersen
Associate Director, Ferring Pharmaceuticals A/S

Apr 26 2017

Course covers biopharmaceutical aspects of biotechnology thoroughly. Good presenters

Patrick John Couzens
Patent Attorney, Société des Produits Nestlé S.A.

Sep 19 2016

An excellent course! Very informative both for beginners and as a refresher.

Sarah Norton
Senior Scientific Officer, Veterinary Medicines Directorate

Apr 27 2016

I liked the course and would recommend this to work colleagues

Anna Woźniak
Valeant Sp. z o.o. Sp. j.

Apr 27 2016

Very comprehensive and intense. Mostly interested in the science and processes, less interested in patents.

David Cooke
Analytical Science Team Leader, Pfizer Ltd

Sep 19 2016

Course was very well outlined, prepared and presented

Isaac Hanania
LL.M., Boehringer Ingelheim RCV GmbH & Co KG

Sep 19 2016

I really enjoyed this course, it was detailed and interesting. Speakers were very well qualified and good presenters.

Jill Challis
Principal Consultant, NDA Regulatory Science Ltd

Sep 19 2016

Very well organised

Marjon van Dijk
Associate Consultant Chemistry, Manufacturing & Control, Kinesis Pharma B.V

Apr 27 2016

Intense but very interesting course that takes you back to the basis of biotechnology and also provides some inside in regulations

An van Hemelrijck
RA Consultant, PhaRA

Apr 27 2016

Good, useful, complicated

Nicolai Soberg-Hansen
Patent Administrator, Genmab A/S

UK

  • --
  • 42 Technology Ltd
  • 4D Pharma Research Ltd
  • AA Thornton & Co
  • AbbVie
  • Actavis Biologics Ltd
  • Albumedix
  • Albumedix Limited
  • Albumedix Ltd
  • Alere
  • Alizyme Plc
  • Allergan Limited
  • Allergan UK Limited
  • Alta Innovations Ltd
  • AMGEN LTD
  • Antisoma Research Ltd
  • Apothecom Limited
  • Aptuit (Edinburgh) Ltd
  • Archimedes Pharma UK Limited
  • AstraZeneca
  • AstraZeneca R&D Charnwood
  • AstraZeneca UK Ltd
  • Avecia Biotechnology Ltd
  • Avecia Ltd
  • Bayer Healthcare
  • Biogen
  • Biogen Idec Ltd
  • BioReliance Ltd
  • Boehringer Ingelheim International GmbH
  • Bristows LLP
  • Cancer Research UK
  • Catalent Pharma Solutions
  • CCLRC DARESBURY LABORATORY
  • CELLTECH
  • CHI
  • CHIRON VACCINES
  • Chugai Pharma Europe
  • Clinigen Group PLC
  • Covance
  • Cyton Biosciences Ltd
  • D Young & Co LLP
  • Eisai Limited
  • Eli Lilly & Co Ltd
  • Eli Lilly & Company Limited/Elanco Animal Health
  • Eli Lilly & Company Ltd
  • European Medicines Agency
  • EUSA Pharma Ltd
  • Ferring Controlled Therapeutics Ltd
  • French Trade Commission UBI France
  • Genzyme
  • Genzyme Ltd
  • Gilead Sciences International Ltd
  • GILROY FILTRATION LTD
  • GlaxoSmithKline
  • GlaxoSmithKline Research & Development Ltd
  • Gregory Fryer Associates
  • Home Address
  • Hospira UK Limited
  • Icon Clinical Research
  • Idis Limited
  • IDIS LTD
  • IHS Global Insight
  • Imerys Minerals
  • IMS Health UK
  • INVEST NORTHERN IRELAND
  • Ipsen Biopharm Ltd
  • IQVIA
  • J A Kemp & Co
  • Johnson Matthey PLC
  • Kings College London
  • KPMG
  • Leo Pharma
  • Lonza Biologics PLC
  • Lundsberg Consulting
  • Medical Research Council
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicines and Healthcare Products Regulatory Authority
  • MedImmune Ltd
  • Melbourn Scientific Limited
  • MERCK GENERICS UK LTD
  • Merck Sharp & Dohme Ltd
  • Mercury Pharmaceuticals Ltd
  • MHRA
  • Mitsubishi Tanabe Pharma Europe Ltd
  • MSD
  • Murex Biotech Ltd
  • NCL Technology Ventures
  • NDA Regulatory Science Ltd
  • New Zealand Trade and Enterprise
  • Novartis Pharmaceuticals UK Ltd
  • O'MELVENY & MYERS
  • Owen Mumford Ltd
  • PANNONE & PARTNERS
  • Parexel International Ltd
  • Pfizer
  • Pfizer Cambridge
  • Pfizer Global Research & Development
  • Pfizer Limited
  • Pfizer Ltd
  • Pfizer Uk Group Ltd
  • Pfizer Uk Ltd
  • Pharmedd Services Ltd
  • Precipio Consulting
  • Probiotics International Ltd.
  • Real Regulatory Ltd
  • Reckitt Benckiser Healthcare (UK) Ltd
  • Regulink Ltd
  • Regulis Consulting Ltd
  • Roche Products Ltd
  • Rothamsted Research Ltd
  • Sagentia Limited
  • Sanofi Pasteur MSD Ltd
  • Sekisui Diagnostics (UK) Ltd
  • Shire Pharmaceutical Ltd
  • Silence Therapeutics
  • Smith & Nephew Extruded Films
  • Stephen Griggs Ltd
  • Stratagem IPM Limited
  • Takeda Cambridge Limited
  • Taylor Vinters
  • TEFEN EUROPE
  • Teva UK Ltd
  • The Immortality Project
  • The Institute Of Cancer Research: Royal Cancer Hospital
  • UCB Celltech
  • UCB Celltech Limited
  • UCB PHARMA LTD
  • University of Southampton
  • University of Surrey
  • Vectura
  • Vectura Group plc
  • Veterinary Medicines Directorate
  • WDA INTERNATIONAL
  • WebBased Ltd
  • WOOD MACKENZIE
  • Wyeth Pharmaceuticals
  • XENOVA LTD
  • ​Fujifilm Kyowa Kirin Biologics Co. Ltd

Switzerland

  • Abbott Products Operations AG
  • Actelion Pharmaceutical Ltd
  • Alexion Pharma EMEA GmbH
  • Bayer Consumer Care
  • Bayer Consumer Care AG
  • DSM Nutrional Products Ltd
  • Elanco
  • F. Hoffman La Roche AG
  • F. Hoffmann-La Roche
  • F. Hoffmann-La Roche Ltd
  • F. Hoffmann-La Roche Ltd.
  • Galderma
  • Galderma SA
  • GeNeuro
  • Geneva Hospital (HUG)
  • Ispettorato regionale dei Medicamenti
  • Leman Consulting S.A.
  • LimmaTech Biologics AG
  • Lonza AG
  • MCKIERNAN ASSOCIATES GMBH
  • Merck
  • Merck Serono SA
  • Nestle Skin Health - Galderma SA
  • Novartis AG
  • Novartis Animal Health Inc. C/O Elanco
  • Novartis Pharma AG
  • Novartis Vaccines & Diagnostics AG
  • Octapharma AG
  • PHF SA
  • Rosenow Grob Schilling
  • SERONO INTERNATIONAL SA
  • Shire
  • Société des Produits Nestlé S.A.
  • Swedish Orphan Biovitrum AG
  • Swiss Medic
  • Syngenta Crop Protection Munchwilen AG
  • TIllotts Pharma AG
  • World Trade Organisation

France

  • 3X Consultants
  • ALEXION Europe SAS
  • Atlanpole
  • Bayer SAS
  • Becton Dickinson
  • Davidson Rhone Alpes
  • Galderma International
  • GALDERMA R & D
  • Galderma R&D
  • GALDERMA Recherche & Developpement
  • Germain & Maureau
  • HRA Pharma
  • IFP Energies nouvelles
  • Intervet Pharma R&D
  • Ipsen Pharma SAS
  • Laboratoires Galderma
  • LFB Biomedicaments
  • LFB Biotechnologies
  • Merck Serono
  • Merial
  • Merial SAS
  • Novartis Pharma SAS
  • Novbartis - Centre de Biotechnologie
  • QUINTILES SA
  • Sanofi Chimie
  • Sanofi Pasteur SA
  • Sanofi-aventis Groupe
  • Sanofi-Aventis R&D
  • Sartorius Stedim Biotech
  • Science Union SA
  • SERONO
  • Servier
  • Societe HTL
  • Technologie Servier
  • Vetoquinol SA

Germany

  • ABBOTT GmbH & Co KG
  • Alfred E Tiefenbacher GmbH & Co KG
  • Bayer AG
  • Bayer Consumer Care AG
  • Bayer Pharma AG
  • BIO GENEVIX AG
  • Boehringer Ingelheim
  • Boehringer Ingelheim Animal Health GmbH
  • Boehringer Ingelheim Pharma GmbH & Co KG
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Boehringer Ingelheim Vetmedica GmbH
  • CSL Behring GmbH
  • European Patent Office
  • FUJISAWA GmbH
  • Kaesler Nutrition
  • Kaesler Nutrition GmbH
  • Klifovet A.G.
  • Medac GmbH
  • Merck KGaA
  • MICROMET AG
  • Novartis Deutschland GMBH
  • ORPHAN EUROPE
  • Protagen Protein Services GmbH
  • Ratiopharm GmbH
  • Roche Diagnostics GmbH
  • Sartorius Stedim Biotech GmbH
  • Vita 34 AG

Denmark

  • Albumedix Ltd
  • Alk Abello A/S
  • Ascendis Pharma A/S
  • Bavarian Nordic
  • BAVARIAN NORDIC A/S
  • Chr. Hansen Holding A/S
  • Danish Health and Medicines Authority
  • DuPont Nutrition Biosciences ApS
  • Ferring Pharmaceuticals A/S
  • Genmab
  • Genmab A/S
  • Genmab AS
  • Jusmedico Law Firm
  • Leo Animal Health As
  • LEO Pharma
  • Leo Pharma A/S
  • Maxygen ApS
  • NNE A/S
  • NNE Pharmaplan A/S
  • Novo A/S
  • Novo Nordisk A/S
  • Novo Nordisk AS
  • Statens Serum Institut
  • Symphogen A/S
  • Tarius A/S

Netherlands

  • Akzo Nobel NV
  • Amgen Europe BV
  • Astellas BV
  • Centocor BV
  • De Vries & Metman
  • GENENCOR
  • Genmab
  • Genmab B.V
  • Genmab B.V.
  • Genmab BV
  • Genzyme Europe BV
  • Jadis Additiva bv
  • Kinesis Pharma
  • Kinesis Pharma B.V
  • Kinesis Pharma B.V.
  • Kinesis Pharma BV
  • Merck Sharp & Dohme
  • Merus NV
  • MSD/NV Organon
  • SIMMONS & SIMMONS
  • Tanatex Chemicals BV
  • TNO QUALITY OF LIFE

Belgium

  • BAXTER
  • Biosource Europe
  • Elanco Animal Health
  • EuropaBio
  • Glaxo Smithkline Biologicals
  • IMEC vzw
  • Janssen Pharmaceutica NV
  • Omrix Biopharmaceuticals NV/SA
  • PhaRA
  • Total Petrochemicals and Refining SA/NV
  • Toxikon Europe N. V
  • UCB Pharma SA
  • Zoetis Belgium S.A.

Spain

  • BioFabri
  • C Z Veterinaria S.A.
  • Chemo Espana SL
  • CZ Veterinaria, S.A
  • Dentaid SL
  • Digna Biotech SL
  • ESTEVE
  • Gadea Grupo Farmaceutico
  • Laboratorios Leti SL
  • Merck SL
  • MSD
  • Mylan Pharmaceuticals SL
  • SCHERING SPAIN SA

Ireland

  • Helsinn Birex Pharmaceuticals Ltd
  • Irish Patents Office
  • MyBio Ltd.
  • Pfizer Ireland Pharmaceuticals
  • Pfizer Ltd
  • Shandon Clinical Trials Limited
  • Shire Pharmaceuticals Ireland Limited
  • Theravance Biopharma
  • Wyeth Biotech
  • Wyeth Medica Ireland

United States of America

  • ARADIGM CORPORATION
  • BD
  • Boehringer Ingelheim Pharmaceuticals Inc
  • Boehringer Ingelheim Vetmedica Inc
  • Hoffmann-La Roche Incorporated
  • Medimmune
  • MPEG LA
  • Reckitt Benckiser Pharmaceuticals Inc
  • Shire
  • UCB Inc

Sweden

  • APL
  • Aros Patent AB
  • AstraZeneca
  • AstraZeneca AB
  • AstraZeneca R & D Sodertalje
  • INTERVACC AB
  • Q Advance Compliance & Validation AB
  • Recipharm AB
  • Zacco Sweden AB

Italy

  • Bayer CropScience srl
  • chiesi farmaceutici
  • Chiesi Farmaceutici SPA
  • Menarini Biotech Srl
  • Merck group
  • Merck Serono SpA

Austria

  • Amgen GmbH
  • AOP Orphan Pharma
  • BIOMIN Holding GmbH
  • Boehringer Ingelheim RCV GmbH & Co KG
  • Sandoz GmbH

Turkey

  • Arven Ilac
  • Boehringer Ingelheim Ilaç Tic. A.S.
  • Sanovel Pharmaceutical INC
  • Turgut Ilac AS
  • U.S. Commercial Service Turkey

Finland

  • Kolster OY AB
  • Medix Biochemica
  • Orion Corporation
  • Orion Corporation Orion Pharma

Croatia

  • Agency for Medicinal Products and Medical Devices of Croatia (HALMED)
  • Nicro d.o.o.
  • Pliva Croatia Ltd

Saudi Arabia

  • ARMED FORCES HOSPITAL
  • Saudi Food and Drug Authority
  • The Cooperation Council For The Arab States Of The Gulf

Egypt

  • EGYPTIAN EXPORTERS ASSOCIATION
  • EVA PHARMA

Israel

  • Elcam Medical Ltd
  • Teva Pharmaceutical Industries Ltd

Norway

  • ALPHARMA AS
  • Bergen Teknologioverforing AS

Portugal

  • Industrial Property Portuguese Office
  • JABA FARMACEUTICA S.A

Russia

  • MOSCOW MEDICAL ACADEMY
  • Stada Pharmdevelopment LLC

Slovenia

  • Billev farmacija vzhod d.o.o
  • LEK Pharmaceuticals d.d.

Australia

  • Specialised Therapeutics Australia Pty Ltd

Canada

  • Lifesciences British Columbia

Czech Republic

  • Zentiva Group AS

Greece

  • NOVO NORDISK AS

Hungary

  • Gedeon Richter

India

  • Lupin Limited

Indonesia

  • Bio Farma

Iran

  • Cobel Darou

Malta

  • Alvogen Malta Operations ROW

Mexico

  • DIAGNOSTICA

Poland

  • Valeant Sp. z o.o. Sp. j.

Enrol now

Multiple colleagues?
Talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra BEER
Training expert

+44 (0)20 7749 4749

inhouse@ipi.academy